Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

regimen

MPT

Cancer Type
Hematologic, Multiple Myeloma
Intent
Palliative
Regimen Category
Evidence-Informed
Funding Program
ODB - General Benefit prednisone Exceptional Access Program thalidomide - Multiple myeloma in patients ≥65 years of age in combination with melphalan and prednisone, with specific criteria

Regimen Monograph

Jun 2019

Patient Info Sheet

Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.

Last Updated: July 27, 2026